SLRN vs. OCS, STTK, KALV, ABUS, APLT, TBPH, TVTX, CMPS, FULC, and IGMS
Should you be buying Acelyrin stock or one of its competitors? The main competitors of Acelyrin include Oculis (OCS), Shattuck Labs (STTK), KalVista Pharmaceuticals (KALV), Arbutus Biopharma (ABUS), Applied Therapeutics (APLT), Theravance Biopharma (TBPH), Travere Therapeutics (TVTX), COMPASS Pathways (CMPS), Fulcrum Therapeutics (FULC), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical preparations" industry.
Acelyrin (NASDAQ:SLRN) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, community ranking, risk, analyst recommendations, media sentiment, earnings and profitability.
In the previous week, Oculis had 7 more articles in the media than Acelyrin. MarketBeat recorded 8 mentions for Oculis and 1 mentions for Acelyrin. Acelyrin's average media sentiment score of 0.55 beat Oculis' score of 0.03 indicating that Acelyrin is being referred to more favorably in the media.
Acelyrin presently has a consensus price target of $23.67, suggesting a potential upside of 458.18%. Oculis has a consensus price target of $29.14, suggesting a potential upside of 143.87%. Given Acelyrin's higher probable upside, equities research analysts clearly believe Acelyrin is more favorable than Oculis.
Oculis has higher revenue and earnings than Acelyrin.
87.3% of Acelyrin shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Oculis' return on equity of 0.00% beat Acelyrin's return on equity.
Oculis received 8 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 85.00% of users gave Oculis an outperform vote while only 56.25% of users gave Acelyrin an outperform vote.
Summary
Oculis beats Acelyrin on 9 of the 12 factors compared between the two stocks.
Get Acelyrin News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acelyrin Competitors List
Related Companies and Tools
